Invivo Therapeutics Holdings (NVIV) 2.9000 $NVIV
InVivo Therapeutics executes 1:4 reverse stock split
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 9:02AM CDT
InVivo Therapeutics Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ
Business Wire - Wed Apr 08, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the implementation of its previously disclosed 1-for-4 reverse stock split as of today, April 8, 2015, a key step in preparation for its planned uplisting to the NASDAQ Capital Market.
InVivo Therapeutics Announces New Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Wed Apr 01, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that UC Davis Medical Center in Sacramento, CA has been added as a clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The medical center serves a 65,000 square-mile territory that includes 33 counties and 6 million residents across northern and central California.
InVivo Therapeutics Announces University of Kansas Medical Center as New Site for Neuro-Spinal Scaffold Clinical Trial
Business Wire - Mon Mar 30, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of Kansas Medical Center in Kansas City, KS has been added as a clinical site in the company's ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Paul Arnold, MD, Professor of Neurosurgery and Vice Chair of Research, has been named Principal Investigator at the site.
InVivo Revolutionizing Spinal Cord Injury
Jason Napodano, CFA - at Seeking Alpha - Fri Mar 27, 2:47PM CDT
InVivo Therapeutics Exhibiting at 66th Southern Neurosurgical Society Annual Meeting
Business Wire - Fri Mar 27, 11:30AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the company is exhibiting at the 66th Southern Neurosurgical Society (SNS) Annual Meeting being held in Naples, Florida on March 25-28, 2015. Tom Ulich, MD, InVivo's Chief Scientific Officer, and Lorianne Masuoka, MD, InVivo's Chief Medical Officer, are presenting intraoperative videos from the company's ongoing Investigational Device Exemption (IDE) pilot study, which has enrolled two subjects thus far. The videos provide an update to the neurosurgical community on the company's investigational Neuro-Spinal Scaffold novel implantation techniques, which until InVivo's pilot study, had never been performed in patients with spinal cord injury.
InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for Anticipated Completion of Ongoing Pilot Trial
Business Wire - Thu Mar 26, 8:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the reopening of subject enrollment for the company's ongoing Investigational Device Exemption (IDE) pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Barring significant safety issues, the final three subjects of this pilot trial will be enrolled concurrently and without mandatory safety hold between enrollment of each subject. To date, there have been no reported serious safety events related to the Neuro-Spinal Scaffold or the procedure to implant the Neuro-Spinal Scaffold with the study's first and second subjects, and InVivo has been approved by FDA and the Data Safety Monitoring Board (DSMB) to move forward with the study. As specified in the study protocol, the DSMB is a committee of independent clinical research experts charged with examining the safety data accumulated during the trial.
InVivo adds a third site to its Neuro-Spinal Scaffold study
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 3:45PM CDT
InVivo Therapeutics Announces Keck Hospital of University of Southern California as New Site for Neuro-Spinal Scaffold Clinical Trial
Business Wire - Wed Mar 25, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Keck Hospital of University of Southern California (USC) in Los Angeles, CA has been added as a clinical site in the company's ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The Keck Hospital of USC is a 401-bed acute care hospital for the Keck Medical Center of USC, a system that comprises more than 500 faculty physicians. Patrick Hsieh, MD, Director of Neurosurgery Spine Program and Associate Professor of Neurological Surgery, has been named Principal Investigator at the site.
InVivo Therapeutics to reverse split stock 1:4
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 9:08AM CDT
InVivo Therapeutics Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ
Business Wire - Tue Mar 24, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that its Board of Directors has approved a 1-for-4 reverse stock split of its issued and outstanding common stock in preparation for its planned uplisting to the NASDAQ Capital Market. The company anticipates the reverse stock split to become effective and its common stock to begin trading on a post-split basis at the open of trading on April 8, 2015, contingent upon approval from the Financial Industry Regulatory Authority (FINRA).
InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update
Business Wire - Wed Mar 11, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2014.
New medical chief at InVivo Therapeutics
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 7:23AM CST
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer
Business Wire - Mon Feb 09, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Lorianne Masuoka, MD, as Chief Medical Officer (CMO), effective March 2, 2015. She will be taking over for the interim CMO, Lou Vaickus, MD, who is also Founder & President of akta Pharmaceutical Development LLC, a life sciences consulting company.
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 4.18 (-0.07), BLUE: 126.34 (+1.49), ZIOP: 10.13 (+0.43), MYGN: 35.50 (-0.41), PSTI: 2.81 (unch), PFE: 35.44 (+0.41), XON: 42.89 (+0.87), TKMR: 18.19 (+0.59), ASPX: 100.58 (+0.10), MNKD: 5.25 (unch), HSP: 87.75 (+0.10), ZTS: 47.17 (+0.62), ANTM: 153.92 (+0.43), WMGI: 26.30 (+0.32), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), THOR: 42.15 (-0.04), TEVA: 66.37 (-0.77), ABBV: 62.00 (+1.68), SNY: 52.35 (+0.48), ARNA: 4.55 (+0.01)
InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board
Business Wire - Thu Feb 05, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chairman of InVivo's Board of Directors, effective immediately. Perrin has served as a Board member and Chief Executive Officer of the company since January 2014. John A. McCarthy, Jr., current non-executive Chairman of the Board since September 2013, will remain on the Board and will continue to chair the Audit Committee.
InVivo Therapeutics: Long Idea Playing Out With Room To Run
JMY Investments - at Seeking Alpha - Mon Feb 02, 2:01PM CST
InVivo Therapeutics Announces $12 Million Registered Direct Offering
Business Wire - Thu Jan 29, 7:02AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received commitments from two dedicated health care funds to purchase an aggregate of $12 million of the Company's common stock in a registered direct offering.
InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial
Business Wire - Thu Jan 22, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a second subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Carolinas Medical Center, part of the Carolinas HealthCare System in Charlotte, NC. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.
First patient responds well to InVivo Spinal Scaffold
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 7:37AM CST
InVivo Therapeutics executes 1:4 reverse stock split
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 9:02AM CDT
InVivo Therapeutics Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ
Business Wire - Wed Apr 08, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the implementation of its previously disclosed 1-for-4 reverse stock split as of today, April 8, 2015, a key step in preparation for its planned uplisting to the NASDAQ Capital Market.
InVivo Therapeutics Announces New Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Wed Apr 01, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that UC Davis Medical Center in Sacramento, CA has been added as a clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The medical center serves a 65,000 square-mile territory that includes 33 counties and 6 million residents across northern and central California.
InVivo Therapeutics Announces University of Kansas Medical Center as New Site for Neuro-Spinal Scaffold Clinical Trial
Business Wire - Mon Mar 30, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of Kansas Medical Center in Kansas City, KS has been added as a clinical site in the company's ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Paul Arnold, MD, Professor of Neurosurgery and Vice Chair of Research, has been named Principal Investigator at the site.
InVivo Revolutionizing Spinal Cord Injury
Jason Napodano, CFA - at Seeking Alpha - Fri Mar 27, 2:47PM CDT
InVivo Therapeutics Exhibiting at 66th Southern Neurosurgical Society Annual Meeting
Business Wire - Fri Mar 27, 11:30AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the company is exhibiting at the 66th Southern Neurosurgical Society (SNS) Annual Meeting being held in Naples, Florida on March 25-28, 2015. Tom Ulich, MD, InVivo's Chief Scientific Officer, and Lorianne Masuoka, MD, InVivo's Chief Medical Officer, are presenting intraoperative videos from the company's ongoing Investigational Device Exemption (IDE) pilot study, which has enrolled two subjects thus far. The videos provide an update to the neurosurgical community on the company's investigational Neuro-Spinal Scaffold novel implantation techniques, which until InVivo's pilot study, had never been performed in patients with spinal cord injury.
InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for Anticipated Completion of Ongoing Pilot Trial
Business Wire - Thu Mar 26, 8:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the reopening of subject enrollment for the company's ongoing Investigational Device Exemption (IDE) pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Barring significant safety issues, the final three subjects of this pilot trial will be enrolled concurrently and without mandatory safety hold between enrollment of each subject. To date, there have been no reported serious safety events related to the Neuro-Spinal Scaffold or the procedure to implant the Neuro-Spinal Scaffold with the study's first and second subjects, and InVivo has been approved by FDA and the Data Safety Monitoring Board (DSMB) to move forward with the study. As specified in the study protocol, the DSMB is a committee of independent clinical research experts charged with examining the safety data accumulated during the trial.
InVivo adds a third site to its Neuro-Spinal Scaffold study
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 3:45PM CDT
InVivo Therapeutics Announces Keck Hospital of University of Southern California as New Site for Neuro-Spinal Scaffold Clinical Trial
Business Wire - Wed Mar 25, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Keck Hospital of University of Southern California (USC) in Los Angeles, CA has been added as a clinical site in the company's ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The Keck Hospital of USC is a 401-bed acute care hospital for the Keck Medical Center of USC, a system that comprises more than 500 faculty physicians. Patrick Hsieh, MD, Director of Neurosurgery Spine Program and Associate Professor of Neurological Surgery, has been named Principal Investigator at the site.
InVivo Therapeutics to reverse split stock 1:4
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 9:08AM CDT
InVivo Therapeutics Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ
Business Wire - Tue Mar 24, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that its Board of Directors has approved a 1-for-4 reverse stock split of its issued and outstanding common stock in preparation for its planned uplisting to the NASDAQ Capital Market. The company anticipates the reverse stock split to become effective and its common stock to begin trading on a post-split basis at the open of trading on April 8, 2015, contingent upon approval from the Financial Industry Regulatory Authority (FINRA).
InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update
Business Wire - Wed Mar 11, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2014.
New medical chief at InVivo Therapeutics
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 7:23AM CST
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer
Business Wire - Mon Feb 09, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Lorianne Masuoka, MD, as Chief Medical Officer (CMO), effective March 2, 2015. She will be taking over for the interim CMO, Lou Vaickus, MD, who is also Founder & President of akta Pharmaceutical Development LLC, a life sciences consulting company.
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 4.18 (-0.07), BLUE: 126.34 (+1.49), ZIOP: 10.13 (+0.43), MYGN: 35.50 (-0.41), PSTI: 2.81 (unch), PFE: 35.44 (+0.41), XON: 42.89 (+0.87), TKMR: 18.19 (+0.59), ASPX: 100.58 (+0.10), MNKD: 5.25 (unch), HSP: 87.75 (+0.10), ZTS: 47.17 (+0.62), ANTM: 153.92 (+0.43), WMGI: 26.30 (+0.32), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), THOR: 42.15 (-0.04), TEVA: 66.37 (-0.77), ABBV: 62.00 (+1.68), SNY: 52.35 (+0.48), ARNA: 4.55 (+0.01)
InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board
Business Wire - Thu Feb 05, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chairman of InVivo's Board of Directors, effective immediately. Perrin has served as a Board member and Chief Executive Officer of the company since January 2014. John A. McCarthy, Jr., current non-executive Chairman of the Board since September 2013, will remain on the Board and will continue to chair the Audit Committee.
InVivo Therapeutics: Long Idea Playing Out With Room To Run
JMY Investments - at Seeking Alpha - Mon Feb 02, 2:01PM CST
InVivo Therapeutics Announces $12 Million Registered Direct Offering
Business Wire - Thu Jan 29, 7:02AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received commitments from two dedicated health care funds to purchase an aggregate of $12 million of the Company's common stock in a registered direct offering.
InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial
Business Wire - Thu Jan 22, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a second subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Carolinas Medical Center, part of the Carolinas HealthCare System in Charlotte, NC. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.
First patient responds well to InVivo Spinal Scaffold
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 7:37AM CST
